ICYMI, this week we had articles about coverage from the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting, the availability of UCB's bimekizumab, FDA breakthrough therapy designation to QTORIN rapamycin for microcystic lymphatic malformations, and more.
What are some of the challenges and triumphs in using biologics for atopic dermatitis? Abby L. Allen, RN, NP, shares insights at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting.
A poster presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting found once daily roflumilast cream 0.15% safely and significantly improved atopic dermatitis.
Late-breaking data adds important safety and efficacy data for leukotriene receptor antagonists augmentation in chronic urticaria treatment.
Kamran H. Imam, MD, hopes to unlock insights into the atopic disease burden among Native American populations.
Marcella R. Aquino details issues in differential diagnosis for rashes that mimic allergic skin conditions at the ACAAI Annual Meeting.
Session at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting explored issues in understanding and testing for physical urticaria.
Keep up with the latest headlines in dermatology from the past week, including the rise of teledermatology platforms leading patients to opt out of in-person consultations, WHO and ILO estimates of non-melanoma skin cancer deaths attributable to outdoor work in the sun, and more.
In this week’s Pointers With Portela, the 208SkinDoc reviews medical health insurance on his podcast.
2023 has been complete with numerous innovations in the dermatology space, including in atopic dermatitis, psoriasis, alopecia areata, and more.
Dermatology encompasses cosmetics, unregulated products, OTC drugs, OTC devices, prescription devices, and prescription drugs, whether oral, injectable, or topical.
In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.
Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.
In honor of National Healthy Skin Month, it is the perfect time to encourage patients to integrate gentle laser treatments into their yearly routine to maintain healthy, radiant skin.
Experts discuss insights and hot topics stemming from this year's Science of Skincare Summit, including upcoming innovations and considerations in dermatology.
Label warnings may affect the initiation of new treatment and real-world switching patterns for psoriasis patients starting treatment with risankizumab.
Dermatology Times, the SDPA, and more are celebrating the invaluable contributions of nurse practitioners in dermatology this NP Week (November 12-18).
This week’s collection of the latest dermatologic studies covers atypical molluscum contagiosum lesions with a CD30-positive T-cell lymphoid infiltrate, comorbidities in pediatric psoriasis, tralokinumab for adolescents with severe AD, and intralesional bleomycin combined with lidocaine for recalcitrant keloid scars.
Almirall, Absci Partner to Develop AI-Designed Therapies for Dermatologic Conditions
Experts Heather Woolery-Lloyd, MD; Chesahna Kindred, MD, MBA, FAAD; Gary M. Owens, MD; and Renata Block, MMS, PA-C, discuss the evolving landscape of vitiligo, particularly from an economic lens.
There are currently no FDA-approved therapies for the rare, genetic disease.
Experts discuss enhancing patient outcomes, the "mounting mutiny" against topicals, and more.
Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the US and is projected to maintain a substantial market lead over ritlecitinib.
Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.
November is Native American Heritage Month. Access to dermatological health care has been a persistent challenge for individuals in the AIAN community.
Hyperhidrosis is not rare. According to the International Hyperhidrosis Society, approximately 385 million people worldwide live with hyperhidrosis.
Germany will be the first country where lebrikizumab will be available for prescription, with a subsequent rollout across European countries throughout 2024.
Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, discusses Apex Dermatology's Purple Heart Project.
Kwatra presented on the unmet need for itch improvement in patients with skin of color.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.